What are your treatment options for HER2 over-expressing metastatic breast cancer in a patient whose LVEF decreased to <50% from normal baseline on HER2-directed therapy and EF fails to improve after holding therapy for 2 months?
Answer from: Medical Oncologist at Academic Institution
The decision for stopping HER2 therapy for cardiomyopathy should be weighed against the risk of their metastatic disease progressing on suboptimal therapy. With closer monitoring and help from a cardiologist to optimize medical management, I have been able to continue effective anti-HER2 therapy in ...
Comments
Medical Oncologist at Colorado Permanente Medical Group Hematology & Oncology Appreciate your pragmatic answer.
Appreciate your pragmatic answer.